FindTrial
Sign In

A prospective, double-blind, randomized controlled trial of TCM syndrome differentiation combined with andis classification in the treatment of stage IV diabetic kidney disease of spleen kidney qi deficiency type

A prospective, double-blind, randomized controlled trial of TCM syndrome differentiation combined with andis classification in the treatment of stage IV diabetic kidney disease of spleen kidney qi deficiency type

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000037506
Enrollment
Unknown
Registered
2020-08-28
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic kidney disease

Interventions

Experimental group:Jianpi Yishen prescription
Control group:Conventional treatment

Sponsors

Longhua Hospital Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) The clinical diagnosis of DKD stage IV was spleen kidney qi deficiency type; (2) Aged 18 to 75 years old; (3) The patients were informed and signed the informed consent.

Exclusion criteria

Exclusion criteria: (1) Urinary sediment indicates active hematuria; (2) The renal function decreased rapidly in a short time; (3) Acute infection and acute complications of diabetes (diabetic ketoacidosis, hyperglycemia and hyperosmolarity); (4) Severe heart, brain, liver, kidney and other organic diseases, malignant tumor and mental disease patients; (5) Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Glomerular filtration rate;—

Countries

China

Contacts

Public ContactZhang Xianwen

Longhua Hospital Shanghai University of Traditional Chinese Medicine

zxw0202@163.com+86 13564567339

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026